Psilocybin has very low physical toxicity. Based on animal studies, a 60-kilogram person would need to ingest roughly 17 kilograms of fresh psilocybin mushrooms to reach a potentially lethal dose. For context, a typical high dose in clinical research is 30 to 40 milligrams, a fraction of what would be needed to cause fatal poisoning. Only three deaths in the medical literature have been attributed directly to magic mushroom toxicity. That said, psilocybin is not without risks, and the word “toxic” covers more ground than just lethality.
How Far Away Is a Lethal Dose?
Toxicologists measure a substance’s danger partly through its LD50, the dose that kills half of test animals. For psilocybin in rats, that number is 280 mg/kg of body weight, administered intravenously. In mice, it ranges from about 275 to 420 mg/kg depending on the method of administration. These are extremely high relative to the doses that produce psychoactive effects in humans, where perceptual changes begin at roughly 0.04 to 0.075 mg/kg.
The gap between an active dose and a dangerous dose is enormous compared to most drugs. A person would have to consume hundreds of times a normal dose to approach lethal territory. This wide margin is one reason psilocybin consistently ranks among the least harmful substances in formal drug harm assessments.
Psilocybin’s Rank Among Other Drugs
In a multi-criteria decision analysis evaluating 19 drugs for harm to both users and society, psilocybin mushrooms scored a 3 out of 100. For comparison, alcohol scored 73, cocaine scored 60, tobacco scored 35, and fentanyl topped the list at 90. Separate analyses in the UK and EU similarly ranked psilocybin and other hallucinogens as among the least harmful drugs overall. These rankings factor in not just toxicity but also dependence potential, social harm, and healthcare burden.
What It Does to Your Heart and Blood Pressure
Psilocybin temporarily raises heart rate and blood pressure in a dose-dependent way. In clinical studies, systolic blood pressure typically peaks between 138 and 155 mmHg, and heart rate rises to somewhere in the 80s or low 90s beats per minute. These changes are comparable to moderate physical exercise and resolve within a few hours. Across multiple clinical trials, none of these cardiovascular effects required medical intervention.
For someone with no heart conditions, these transient bumps are generally insignificant. But for people with uncontrolled hypertension or cardiovascular disease, even a modest spike could matter. Clinical trials routinely screen out participants with serious heart conditions for this reason.
Effects on the Liver and Kidneys
Psilocybin does not appear to cause liver damage. In clinical studies, liver enzyme levels remain within normal ranges after administration. Kidney effects are less studied but appear rare. One documented case involved a 15-year-old who developed acute kidney injury 36 hours after eating psilocybin mushrooms. His creatinine levels (a marker of kidney function) spiked to nearly four times the normal range. Researchers suspected the injury may have resulted from the drug’s effects on blood flow to the kidneys rather than direct chemical damage to kidney tissue. He recovered fully within three months with no lasting effects.
This remains an isolated case report, not a pattern, but it suggests that kidney stress is at least possible, particularly at higher doses or in younger users.
Brain Effects: Damage or Growth?
Psilocybin does not cause the kind of brain cell death associated with neurotoxic substances like methanol or MDMA at high doses. Reviews of the pharmacological evidence describe psychedelics as “physiologically safe” in that they do not provoke physical toxicity to neural tissue.
In fact, the evidence points in the opposite direction. A single dose of psilocybin activates genes in the prefrontal cortex and hippocampus that are involved in building and strengthening connections between brain cells. Animal studies show increased dendritic complexity, meaning neurons grow more elaborate branching structures that improve communication between cells. These structural changes outlast the acute effects of the drug by days or weeks. Repeated doses have been shown to stimulate the growth of new neurons and raise levels of a key brain growth factor for up to a month after treatment.
There is one nuance worth noting. In mice, low doses of psilocybin increased the generation of new brain cells, but higher doses actually decreased it two weeks later. The relationship between dose and long-term brain cell growth appears to follow an inverted curve rather than a simple “more is better” pattern.
Psychological Risks
The most meaningful dangers of psilocybin are psychological, not physical. The substance produces powerful alterations in perception, emotion, and sense of self. In unsupported settings, this can trigger intense anxiety, panic, paranoia, or confusion. A small number of deaths have been linked not to the drug’s pharmacology but to dangerous behavior during intoxication, such as falls from heights.
People with a personal or family history of psychotic disorders face a distinct risk. Clinical trials universally exclude individuals with schizophrenia, bipolar disorder, schizoaffective disorder, or a history of psychotic episodes. This exclusion is largely based on case reports rather than controlled studies, but the concern is serious enough that no major research group has been willing to test psilocybin in these populations until very recently.
A condition called hallucinogen persisting perception disorder (HPPD) is another potential consequence. People with HPPD experience persistent visual disturbances, such as trailing images, halos, or flickering, long after the drug has left their system. A web-based survey of over 2,400 psychedelic users estimated the prevalence at about 4.2%. HPPD can be distressing but is not related to structural brain damage.
Mixing Psilocybin With Other Drugs
The most dangerous drug interaction involves combining psilocybin with monoamine oxidase inhibitors (MAOIs), a class of antidepressant that also appears in some traditional plant brews. This combination can cause serotonin toxicity, a potentially life-threatening condition marked by muscle rigidity, dangerously high fever, seizures, and extreme fluctuations in vital signs.
Combining psilocybin with more common antidepressants like SSRIs presents a lower risk. Because neither SSRIs nor psilocybin alone strongly increases the concentration of serotonin at the synapse in the way MAOIs do, the combination is less likely to trigger severe serotonin toxicity. However, SSRIs can blunt or alter the psychedelic experience, and mild serotonin-related side effects remain possible. The risk exists along a spectrum, and the severity depends heavily on which specific drugs are involved and at what doses.